SVA - Sinovac

[suze]

Sinovac to Present at Piper Jaffray Health Care Conference

sinovac the producer of the vaccinces for h1n1 & h5n1 is presenting at the piper jaffaray conference.
recently piperjaffaray upgraded sinovac.
but the stock has been tanking after the upgrade. might be a good time in anticipation of the conference presentation.

[Nikko]

It's again lift- off.

Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities

Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development

[dgwd6388]

I'm not very familiar with SVA or any other vaccine manufactures out there but i have traded this stock, and it seems to me that there are so many of these h1n1 vaccine making companies out there that this one is nothing special. What will happen to this stock when the h1n1 epidemic comes to an end and there are no more orders for the vaccine? I'm not a short, and i don't own anymore shares of this stock but it seems to me the upside for this stock is limited as the h1n1 epidemic is not a big concern anymore.

[Nikko]

Take a look at its Animal Rabies Vaccine it could be SVA's biggest earner
by the end of 2010.
Since 2008, China has implemented compulsory rabies vaccination for
dogs. SVA has developed the only Chinese inactivated animal rabies
vaccine - existing domestic players are only able to supply attenuated
animal rabies vaccines. Animal rabies vaccine is the most cost-
effective strategy for preventing rabies in humans, by eliminating
rabies in dogs. SVA is expected to launch the vaccine in China's
veterinary market in 2010, and has estimated its own market share of
the animal rabies vaccine market will be about $147 million (which is
around 20% of Chinese market).
$147m not bad

In short time the Q4 results will be superb.
Also in one month, SVA is expected to sell 2-in-1(seasonal flu and H1N1)
vaccine.
Over time, SVA has been changing to a long term deal. In the coming
months and years, you can expect a constant up trend and more frequent
jumps. As a result, short traders and busy trading will not win as
much as long term holders.

That's mine opinion and many others.(see google forum thanks to jimA)

[Nikko]

Chinese Vaccine(SVA) to treat swine flu in India

Chinese Vaccine to treat swine flu in India | TradingMarkets.com

Sinovac Finds India Partner for H1N1 Vaccine -- Seeking Alpha

SVA is also much in the brick-building phase in creating a worldwide
market access for itself; Hong Kong, Mexico and India.
Expected next earnings release on 4/8/2010.

Sinovac Biotech Ltd (SVA) Corporate Event Announcement Notice | TradingMarkets.com

Patience will result in very good returns for SVA and its
shareholders